Shepperd Pratt Health System, University of Maryland School of Medicine(7.6 mi away)Contact
+21 other location
This is a multi-site, randomized, open-label, effectiveness trial comparing three treatment
arms for Major Depressive Disorder (MDD) patients with TRD who are currently on ongoing,
stable and adequate antidepressant therapy (ADT). Adequate ADT is defined as a
therapeutically sufficient dose for a sufficient treatment period, which would be expected to
be effective as listed in the MGH Antidepressant Treatment Response Questionnaire (ATRQ).
Patients will be randomized in a 1:1:1 fashion to one of three open-label treatment arms: a)
aripiprazole augmentation, b) rTMS augmentation, and c) switching to venlafaxine XR or
Repetitive Transcranial Magnetic Stimulation (rTMS)
Clinical Study Identifier
Massachusetts General Hospital
Last Modified on
10 September 2020
How clear was the trial content above?
Adding a note
Select a piece of text and start making personal notes.
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.